<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180450</url>
  </required_header>
  <id_info>
    <org_study_id>SCLnow-IMIMH-04</org_study_id>
    <nct_id>NCT03180450</nct_id>
  </id_info>
  <brief_title>The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)</brief_title>
  <official_title>The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sclnow Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sclnow Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of the study is to evaluate the safety and efficacy of human umbilical cord
      mesenchymal stem cells (hUC-MSC) in treating heart failure patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, paralleled study. Patients will be divided into two groups of treatment
      and control. all of them will receive conventional treatment based on specific condition,
      including digitalis, milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme
      Inhibitors (ACEI), angiotension receptor blocker (ARB), and antiplatelet aggregation etc.
      Treatment group patients will receive hUC-MSC. Follow-up visit will occur on 3 months, 6
      months, and 12 months after the cell transfusion. Vital signs, blood routine test, urine
      routine test, liver function examination, etc, will be placed to evaluate the safety of
      hUC-MSC treatment. And the change of symptoms to evaluate the efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart color ultrasound evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Criteria:
Excellent: ejection fraction improve to &gt; 50%;
Efficient: ejection fraction improved;
Inefficient: ejection fraction same as before treatment;
Exacerbation: ejection fraction declined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single therapy effectiveness evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate criteria:
Recovery: symptoms disappear
Excellent: symptoms improved obviously
Efficient: symptoms improved
Inefficient: symptoms no change or worse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Conventional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)</intervention_name>
    <description>Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conventional treatment</intervention_name>
    <description>The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.</description>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  volunteer to participate in clinical trial, and sign informed consent form

          -  with cardiac failure symptoms, including oppression in chest, breathe hard, lower limb
             edema. And new york heart association class as two to four

          -  heart color ultrasound indicate left ventricular ejection fraction (LVEF) &lt; 40%

          -  content of serum NT-proBNP &gt; 450pg/ml

        Exclusion Criteria:

          -  with severe drug allergy history or allergic constitution

          -  patients were severe infected

          -  with malignant tumor or with high tumor marker

          -  with severe cardiorespiratory dysfunction, hematological system disease

          -  with severe mental disorder, cognitive impairment

          -  with persistent atrial fibrillation, valvular heart disease, dilated cardiomyopathy,
             hypertrophic cardiomyopathy or restrictive cardiomyopathy patients

          -  end-stage renal insufficiency, pregnancy, or breast feeding women

          -  bleeding tendency, active gastrointestinal ulcer

          -  recent have major surgery, stroke, cancer, hepatic function insufficiency or other
             life-threatening condition.

          -  under other therapy that possibly influence MSC security or efficacy

          -  donor: HIV, active hepatitis B/C infection, Syphilitic antibody positive

          -  participant/donor: alcoholism, drug addicted, mental disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nashundalai</last_name>
    <role>Study Director</role>
    <affiliation>Inner Mongolia International Mongolian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Guo, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Guo</last_name>
    <phone>861064368977</phone>
    <email>georgeguo@sclnow.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inner Mongolia International Mongolian Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bahushan</last_name>
      <phone>864715182094</phone>
      <email>bahushan@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Human Umbilical Cord Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

